Clinical Pathology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Division of Rheumatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Autoimmun Rev. 2020 Nov;19(11):102662. doi: 10.1016/j.autrev.2020.102662. Epub 2020 Sep 14.
Systemic Sclerosis is chronic progressive autoimmune disease, characterised by microangiopathy and fibrosis. Due to disease heterogeneity, in terms of extent, severity, and rate of progression, optimal therapeutic interventions are still lacking. Haematopoietic stem cells may be a new therapeutic option in this disease and, although the results of the first trials are encouraging, several issues remain to be addressed. On these bases, the stem cells transplantation is an area of active investigation, and an overview of the current available literature may help to define the role of this therapeutic strategy. Although the promising results, some unmet needs remain, including the transplantation protocols and their effects on immune system, the selection of the ideal patient and the pre-transplant cardiopulmonary evaluations. An improvement in these fields will allow us to optimize the haematopoietic stem cell therapies in SSc.
系统性硬化症是一种慢性进行性自身免疫性疾病，其特征为微血管病和纤维化。由于疾病异质性，在程度、严重程度和进展速度方面，仍然缺乏最佳的治疗干预措施。造血干细胞可能是这种疾病的一种新的治疗选择，尽管最初的试验结果令人鼓舞，但仍有一些问题需要解决。基于这些原因，干细胞移植是一个活跃的研究领域，对现有文献的概述可能有助于确定这种治疗策略的作用。尽管有很有前景的结果，但仍存在一些未满足的需求，包括移植方案及其对免疫系统的影响、理想患者的选择以及移植前心肺评估。这些领域的改善将使我们能够优化 SSc 中的造血干细胞治疗。
Zotero 插件